
Gabapral: New Clinical Data Confirm Its Potential in Pediatric IBS
A new clinical study further supports the efficacy of Gabapral®, a precision psychobiotic containing Bifidobacterium adolescentis PRL2019, in children suffering from Irritable Bowel Syndrome (IBS) with recurrent abdominal pain. Conducted as a multicenter, randomized, double-blind, placebo-controlled trial, the study demonstrated a significant reduction in both the frequency and intensity of abdominal pain. Additionally, children receiving Gabapral® showed improved stool consistency and overall symptom remission compared to the placebo group. These findings reinforce the role of B. adolescentis PRL2019 as a GABA-producing probiotic with potential therapeutic applications in pediatric IBS.